USING CT AND MRI FOR IDENTIFICATION OF ARTERIAL HYPERENHANCEMENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

Authors

  • Turgunov B.Sh (PhD student of Republican Specialized Surgery Center after named V.V Vakhidov, Uzbekistan and Radiology Department of Shaoxing People’s Hospital, China)
  • Khudoykulova M.N (Student of Central Asian Medical Univerity, Fergana, Uzbekistan)
  • Uchtemirov M.U (Graduated student of Radiology Department of Samarkand State of Medical University)

Keywords:

MRI, CT, Hepatocellular carcinoma

Abstract

Given the varied prevalence and clinical settings, there has been some heterogeneity in the clinical guidelines regarding the method of imaging diagnosis for hepatocellular carcinoma (HCC). However, all methods used to diagnose HCC are based on the imaging diagnostic hallmarks of arterial enhancement and portal-delayed washout, as key alterations during hepatocarcinogenesis include elevated arterial flow and reduced portal venous flow. Arterial phase hyperenhancement is defined as enhancement in the arterial phase that is unequivocally greater than that of the surrounding liver according to the current major guidelines. Therefore, the objectives of our study were to compare the identification of hyperenhancement according to various phases on CT and MRI in patients with surgically proven HCCs as a reference standard using qualitative and quantitative imaging analyses.

References

European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943

Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res 2015;45

Yoon JH, Park JW, Lee JM. Noninvasive diagnosis of hepatocellular carcinoma: elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea practice guidelines compared with other guidelines and remaining issues. Korean J Radiol 2016;17:7-24

Park YN. Update on precursor and early lesions of hepatocellular carcinomas. Arch Pathol Lab Med 2011;135:704-715

Hennedige T, Yang ZJ, Ong CK, Venkatesh SK. Utility of noncontrast-enhanced CT for improved detection of arterial phase hyperenhancement in hepatocellular carcinoma. Abdom Imaging 2014;39:1247-1254

Yu JS, Kim YH, Rofsky NM. Dynamic subtraction magnetic resonance imaging of cirrhotic liver: assessment of high SIlesions on nonenhanced T1-weighted images. J Comput Assist Tomogr 2005;29:51-58

Downloads

Published

2023-12-08

How to Cite

Turgunov B.Sh, Khudoykulova M.N, & Uchtemirov M.U. (2023). USING CT AND MRI FOR IDENTIFICATION OF ARTERIAL HYPERENHANCEMENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA. World Bulletin of Public Health, 29, 73-74. Retrieved from https://scholarexpress.net/index.php/wbph/article/view/3516

Issue

Section

Articles